Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Secondary bacterial pneumonia is a frequent complication of influenza, associated with high morbidity and mortality. We hypothesized that treatment with neutralizing influenza A antibody AT10_002 protects against severe secondary pneumococcal infection in a mouse model of influenza A infection. Influenza A (H3N2) virus-infected male C57Bl6 mice were treated intravenously with either AT10_002 or a control 2 days postinfection. Seven days later, both groups were infected with Streptococcus pneumoniae and killed 18 hours later. Mice receiving AT10_002 showed less loss of bodyweight compared with controls (+1% vs -12%, P 1 vs 2.5 × 105 colony-forming units per mg; P 

Original publication





Journal of medical virology

Publication Date





1431 - 1437


Department of Intensive Care, Academic Medical Center, Amsterdam, The Netherlands.


Bronchoalveolar Lavage Fluid, Animals, Mice, Inbred C57BL, Humans, Streptococcus pneumoniae, Pneumonia, Pneumococcal, Disease Models, Animal, Body Weight, Immunologic Factors, Antibodies, Viral, Cytokines, Treatment Outcome, Immunization, Passive, Viral Load, Male, Influenza, Human, Influenza A Virus, H3N2 Subtype, Bacterial Load